AbbVie, Abbott Sued by Perrigo Over AndroGel Delay Conspiracy

May 4, 2020, 5:17 PM

Perrigo Co. sued AbbVie Inc. in Philadelphia federal court Monday, claiming its scheme to delay competition for the blockbuster testosterone booster AndroGel kept the Israeli drugmaker’s generic version off pharmacy shelves.

The antitrust lawsuit also targets AbbVie’s former parent Abbott Laboratories, AbbVie subsidiary Unimed Pharmaceuticals, and Besins Healthcare, a Belgian company that partnered with Unimed to develop AndroGel. It was filed in the U.S. District Court for the Eastern District of Pennsylvania.

Parallel cases have been advancing in the same court for several years. The suits initially accused AbbVie of delaying generic AndroGel through sham litigation and “reverse payment” ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.